Background: Thrombosis plays a crucial role in the morbidity and mortality of coronavirus
disease-19 (COVID-19). About one-third of COVID-19 patients experience a thrombotic …

Emerging evidences prove that the ongoing pandemic of coronavirus disease 2019 (COVID-
19) is strictly linked to coagulopathy even if pneumonia appears as the major clinical …

Abstract Severe coronavirus (COVID-19) infection has been reportedly associated with a
high risk of thromboembolism. Developing macrovascular thrombotic complications …

COVID-19, caused by the SARS-CoV-2 virus, has revealed a complex interplay between
inflammation and coagulation, leading to the emergence of the concept of thrombo …

The novel Corona virus infection (Covid-19) first identified in China in December 2019 has
rapidly progressed in pandemic leading to significant mortality and unprecedented …

Emerging evidence shows that the recent pandemic of coronavirus disease 19 (COVID-19)
is characterized by coagulation activation and endothelial dysfunction. This increases the …

COVID-1 9 is a viral respiratory illness caused by the SARS-CoV-2 infection. In addition to
lung disease, clinical complications of COVID-1 9 include myocardial damage and ischemia …

There is an increasing evidence supporting the existence of coagulopathy in coronavirus
disease 2019 (COVID-19) patients. Most of reports are mainly focused on d-dimer. Our …

Introduction Emerging evidence points to an association between severe clinical
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …

The current COVID-19 pandemic emerged in December 2019, in China, affecting millions of
people worldwide. COVID-19 is mainly a disease of the respiratory system, yet systematic …